Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu on September 3, 2013 and is headquartered in Cambridge, MA.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
87
Frequently Asked Questions
Market cap, also known as market capitalization, is the total market value of a company. It's calculated by multiplying the current market price by the total number of shares outstanding. Editas Medicine Inc market cap is $253.12M.
52 week high is the highest price of a stock in the past 52 weeks, or one year. Editas Medicine Inc 52 week high is $3.94 as of November 22, 2026.
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Editas Medicine Inc 52 week low is $1.63 as of November 22, 2026.
Editas Medicine Inc stock price today is $1.64.
Editas Medicine Inc stock price yesterday was $1.71.
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It's calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company's Market Cap by the Net Profit. Editas Medicine Inc's P/E ratio is -2.65.
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It's calculated by dividing a company's market capitalization by its book value. Editas Medicine Inc P/B ratio is 2.9815.
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It's calculated by averaging the closing stock price over the previous 50 trading days. Editas Medicine Inc 50-day moving average is $2.52.